Recent:

Counter Guard Clinical Interaction Handout

Generated for clinical reference. Verify with licensed medical professionals.

Clinical Assessment Required

This interaction information must be interpreted for individual patients.

Warfarin
Aspirin
Interaction Severity:Major
Major Interaction — FDA Drug Label Classification
Data Quality
Highly Documented

Extensive FDA source data, meta-analyses, and post-market surveillance available.

This indicates source reliability, NOT clinical severity.

Mechanism of Interaction

Combined (PK + PD)

Aspirin inhibits platelet clumping (aggregation) while warfarin prevents the blood from clotting normally. Used together, they attack two separate parts of the clotting system simultaneously, significantly increasing the risk of bleeding.

Technical Detail

Aspirin irreversibly inhibits COX-1-mediated thromboxane A2 synthesis, impairing platelet aggregation. Warfarin inhibits VKORC1, reducing vitamin K-dependent clotting factors (II, VII, IX, X). Co-administration also displaces warfarin from plasma protein binding (albumin), transiently increasing free warfarin concentration. CYP2C9-mediated warfarin metabolism may also be inhibited.

CYP2C9VKORC1COX-1COX-2

Source: FDA Warfarin Label, Section 7; FDA Drug Safety Communication 2012

What This Means Clinically

This interaction is generally manageable. Consider:

  • Absolute indication for combination — document benefit-risk assessment in notes
  • GI bleeding risk is substantially elevated; consider gastroprotective therapy (PPI)
  • INR monitoring frequency should increase significantly when aspirin is initiated or discontinued
  • Assess for signs of bleeding at each encounter: bruising, melena, haematuria
  • Patient education: avoid NSAIDs, ibuprofen, naproxen; all increase bleeding risk further

Management Strategiesfrom FDA Label

  • If combination is clinically necessary, use the lowest effective aspirin dose (75–100 mg daily).
  • Add gastroprotective therapy (PPI) for duration of combination use.
  • Increase INR monitoring to weekly for 4 weeks after aspirin initiation, then monthly.
  • Target INR lower end of therapeutic range where clinically acceptable.
  • Ensure patient carries a medication alert card identifying anticoagulant use.

These are general considerations from FDA labelling. Tailor to your individual patient.

Evidence Documentation

Clinical Studies

Extensive

Multiple RCTs and meta-analyses with large sample sizes.

FDA Label

Complete

Prominently featured in both drug labels with explicit warnings.

Post-Market (FAERS)

8,924reports

2000–2024 — Extensive FAERS reporting history. Leading cause of reported drug-related bleeding events.

Information Limitations

  • Based on US FDA data (updated March 2025)
  • Risk magnitude varies significantly by aspirin dose — low-dose data differs from full analgesic doses
  • Does not account for patient-specific bleeding risk scores (HAS-BLED)
  • Does not include international regulatory perspectives (EMA, TGA)

Always verify with:

  • Current package inserts
  • ACC/AHA anticoagulation guidelines
  • HAS-BLED bleeding risk score
  • Institution-specific anticoagulation protocols

This is reference information to support your clinical judgment. You remain solely responsible for all patient care decisions.

Data last verified: March 12, 2025 — FDA database

Counter Guard provides clinical reference information for educational and professional use. It does not constitute medical advice. Always consult a licensed healthcare professional for treatment decisions.